Table 1.

Demographic and clinical data of COVID-19 patients and healthy controls

	COVID-19	Healthy controls	Significancea
Number of Individuals	49	20
Age in year, median (range)	55 (26–77)	53 (24–81)	0.4800
Male, n (%)	33 (67)	14 (70)	>0.9999
Female, n (%)	16 (33)	6 (30)
Comorbiditiesb
CCI, median (IQR)	1 (3)	NA	NA
BMI, median (IQR)	28.1 (5.4)	NA	NA
Hypertension, n (%)	12 (24.5)	0	0.0056
Diabetes, n (%)	13 (26.8)	0	0.0056
Current smoker, n (%)	2 (4.1)	0	>0.9999
Laboratory analysesb,c
CRPd, median (IQR)	155 (174)	1 (1)	<0.0001
WBCe, median (IQR)	7.6 (4.9)	6.8 (1.8)	0.2730
Neutrophilse, median (IQR)	6.2 (3.9)	3.8 (1.3)	0.0086
Lymphocytese, median (IQR)	0.8 (0.5)	1.9 (0.7)	<0.0001
NLR, median (IQR)	7.4 (7.6)	1.8 (1.3)	0.0002

CCI   Charlson Comorbidity Index, NLR  neutrophil/lymphocyte ratio, NA data not available.

^aTwo-sided Mann–Whitney U and Fisher’s exact tests were performed to determine statistical significance.

^bComorbidities and laboratory analyses data were available from 41 patients.

^cPeak values: CRP. Nadir values: lymphocyte count. WBC and neutrophil count at the time point of the lowest lymphocyte count.

^dmg/L.

^e10⁹ cells/L.

Normal range: CRP < 3 mg/L, WBC 3.5 $\times$10⁹/L to 8.8 $\times$ 10⁹/L, lymphocytes 1.1 $\times$ 10⁹/L to 3.5 $\times$ 10⁹/L, neutrophils 1.6 $\times$ 10⁹/L to 5.9 $\times$ 10⁹/L, monocytes 0.2 $\times$ 10⁹/L to 0.8 $\times$ 10⁹/L.